Dec 20 (Reuters) - The U.S. Food and Drug Administration on Friday approved EliLilly's (LLY.N), opens new tab weight-loss treatment, Zepbound, for obstructive sleepapnea, making it the first ...
“This is the first pharmacologic therapy that can treat obstructive sleepapnea in this way,” says Dan Skovronsky, chief scientific officer at EliLilly. Read More: Is Intermittent Fasting ...
Results that may be inaccessible to you are currently showing.